Thus, our results support the notion that BCR-ABL suppresses IRF8 at the hematopoietic progenitor stages not only to impede cDC development, but also to promote neutropenia in CML. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.